NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.
- Authors:
- IA McNeish, KK Lin, JX Sun, S Goble, A Oza, RL Coleman, CL Scott, G Konecny, AV Tinker, DM O'Malley, R Kristeleit, L Ma, JD Brenton, K Bell-McGuinn, A Oaknin, A Leary, E Mann, H Giordano, R Yelensky, M Raponi, E Swisher
- Journal:
- CLINICAL CANCER RESEARCH
- Citation info:
- Vol. 22
- Publication date:
- 1st Aug 2016
- Full text
- DOI